Back to search
FDAFDA · Food and drugs·Recall number D-0573-2025

RECOMBINATE, [Antihemophilic Factor (Recombinant)], 5 mL vials, Rx Only, Takeda Pharmaceuticals USA, Cambridge, MA 02142, NDC: 00944-2843-01

Published August 13, 2025 · Recall initiated: July 30, 2025

Summary

FDA records drug Class II recall D-0573-2025, published August 13, 2025 and initiated July 30, 2025. Recalling firm: Cardinal Health Inc.; Status: Ongoing; Reported quantity: 3 units; Lot: Lot: TRB23802AC, Expires: 03/18/2026; TRA22804AA, Expires: 10/18/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Cardinal Health Inc.
Distributor
Nationwide Within the U.S.
Lot
Lot: TRB23802AC, Expires: 03/18/2026; TRA22804AA, Expires: 10/18/2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was RECOMBINATE, [Antihemophilic Factor (Recombinant)], 5 mL vials, Rx Only, Takeda Pharmaceuticals USA, Cambridge, MA 02142, NDC: 00944-2843-01 recalled?

Yes. FDA published recall D-0573-2025 on August 13, 2025. Reported hazard: CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

What should I do if I have this product?

Voluntary: Firm initiated · Letter